Symrise Shares - UBS keeps Buy ahead of capital markets day
17.06.2026 - 19:42:50 | ad-hoc-news.de
Edited by ad hoc news Wed Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 19:38 UTC. Details in the imprint.
Symrise (DE000SYM9999) is back on the analyst tape after UBS kept a Buy rating and a 138 euro target ahead of the company's capital markets day. The note, carried by finanzen.net on 06/17/2026, keeps attention on the stock without changing the underlying business story.
All news and analysis on Symrise stock
Use this hub for background, market data, and company updates linked to Symrise stock.
UBS keeps the tone constructive
UBS maintained its Buy view and 138 euro target for Symrise before the capital markets day, according to finanzen.net. That puts the focus on management commentary rather than a fresh model shock.
The company has not announced a new earnings figure in the material provided here. The cleanest read is simple: a dated analyst update is driving the immediate news flow.
Wednesday means operations
For a Wednesday article, the useful follow-up is operational strategy. Symrise sells flavors, fragrances, and ingredients for food, beverages, cosmetics, and pet food, so investors will look for growth, margin, and portfolio signals.
The capital markets day offers a natural checkpoint for those themes. Any update on pricing, mix, or efficiency will matter more than short-term market noise.
What the company sells
Symrise develops flavor and fragrance solutions for consumer goods makers. Its portfolio also includes functional ingredients used in food, drinks, personal care, and pet nutrition.
Where the stock trades today
The shares of Symrise (DE000SYM9999) trade on Xetra at EUR 83.630 as of 06/17/2026, 17:38 UTC.
Symrise stock at a glance
- Company: Symrise AG
- ISIN: DE000SYM9999
- Ticker: SY1G
- Venue: Xetra
- Price (as of 06/17/2026, 17:38 UTC): EUR 83.630
- Market cap: EUR 11.350B
- Sector / Industry: Materials / Specialty Chemicals
- Index membership: DAX
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
